废水处理厂中的抗抑郁剂:发生,转化和急性毒性评估
Weimin Wang1, Jiaxin Zhang1, Ming Hu2
1State Key Laboratory of Water Environment Simulation, School of Environment, Beijing Normal University, Beijing 100875, China.
The Science of the total environment
|August 14, 2023
概括
废水中的抗抑郁剂 (ATD) 涉及新出现的污染物. 它们在水处理厂中的转化产品 (TP) 显示出增强的毒性,需要先进的处理来保护水生生态系统.
科学领域:
- 环境化学环境化学
- 生态毒理学 生态毒理学
- 废水处理 废水处理
背景情况:
- 抗抑郁药 (ATD) 被广泛使用,导致它们在水生环境中存在.
- ATDs是新出现的污染物,具有已证明的生态毒性,对水生生态系统构成风险.
- 城市污水处理厂 (WWTP) 是ATD进入环境的关键途径.
研究的目的:
- 批判性地审查水处理过程中典型的ATD的发生,转化和毒性.
- 突出与ATD及其转化产品 (TP) 相关的环境风险.
- 为先进的废水处理策略提供科学支持,以减轻ATD污染.
主要方法:
- 在WWTP中对ATD发生,转化和毒性的文献综述.
- 在全球范围内对ATD和代谢物度的分析.
- 生物和非生物转化途径和副产品 (TPs) 的识别.
- 使用ECOSAR模型预测急性毒性.
主要成果:
- 全球ATD度在流入水中的范围为72.62-5011.80 ng/L,在废水中的范围为114.48-6992.40 ng/L.
- 消极的清除率表明ATD可能存在于结合体,使治疗复杂化.
- 转化产品 (TPs) 在废水处理过程中形成.
- 与母ATD相比,TP对水生生物具有更强的毒性.
结论:
- 环保产品有助于ATD及其有毒TP的环境传播.
- 由于TP的毒性增加,因此需要对其进行监测和控制.
- 先进的废水处理对于减少ATD污染和保护水生生物至关重要.
更多相关视频
05:46Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation
Published on: August 1, 2018
13.1K
08:00Screening for Endocrine Activity in Water Using Commercially-available In Vitro Transactivation Bioassays
Published on: December 4, 2016
7.6K
相关概念视频
04:01Factors Affecting Solubility
33.5K
Compared with pure water, the solubility of an ionic compound is less in aqueous solutions containing a common ion (one also produced by dissolution of the ionic compound). This is an example of a phenomenon known as the common ion effect, which is a consequence of the law of mass action that may be explained using Le Chȃtelier’s principle. Consider the dissolution of silver iodide:
33.5K
01:25Antidepressant Drugs: Overview
570
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
570
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
438
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
438
01:23Antidepressant Drugs: MAOIs and Other Agents
274
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
274
01:30Electroconvulsive Therapy
69
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
69